Intervention

Liraglutide

ClinicalTrials.gov intervention label

Clinical trials154
Recruiting5
Common conditions25
Lead sponsors shown15

Clinical trials

60 shown
Examination of How the Duration of Fasting and Temporary Stopping of GLP-1 Medications Affect the Amount of Food Left in the Stomach in People Using Liraglutide (Injected), Semaglutide (Taken by Mouth) or Semaglutide (Injected)NCT07225816 · 2025-11-07
RECRUITING
Liraglutide Treatment in Patients With Maturity-onset Diabetes of the Young (MODY)NCT07029009 · 2025-05-08
RECRUITING
Safety, Tolerability and Preliminary Efficacy of Sublingual Liraglutide in Patients With Type 2 Diabetes MellitusNCT05268237 · 2023-04-25
RECRUITING
Effect of Exercise and/or Liraglutide on Vascular Dysfunction and Insulin Sensitivity in Type 2 Diabetes ( ZQL007)NCT03883412 · 2019-02-28
RECRUITING
Liraglutide-bolus vs Glargine-bolus Therapy in Overweight/Obese Type 2 Diabetes Patients (LiraGooD)NCT03087032 · 2019-01-10
RECRUITING
LIROH - Liraglutide for Obesity in HIVNCT06438146 · 2024-05-02
UNKNOWN
Study to Evaluate the Safety and Effectiveness of Saxenda® for Weight Management in Routine Clinical Practice in Taiwan.NCT06283641 · 2024-04-08
COMPLETED
Efficacy and Safety of Liraglutide in the Treatment of Obesity Combined With Metabolism Associated Fatty Liver DiseaseNCT06501326 · 2023-11-01
UNKNOWN
Anti-obesity Pharmacotherapy and InflammationNCT05756764 · 2023-06-01
ACTIVE_NOT_RECRUITING
Effects of GLP-1RA on Body Weight, Metabolism and Fat Distribution in Overweight/Obese Patients With Type 2 Diabetes MellitusNCT05779644 · 2023-02-23
UNKNOWN
A Research Study Comparing Wegovy to Other Weight Management Drugs in People Living With Obesity in AmericaNCT05579249 · 2023-01-19
COMPLETED
LIGHT-MCI Trial: GLP-1 Agonist, SGLT2 Inhibitor, and DPP-4 Inhibitor for MCI Remission in Type 2 DiabetesNCT05313529 · 2022-10-08
COMPLETED
INSPIRE Turkey :A Research Study Looking at the Clinical Parameters Associated With Use and Discontinuation of Saxenda® in Local Clinical Practice in Turkey by Analysing Past Patient Medical RecordsNCT05438186 · 2022-09-01
WITHDRAWN
Effect of Liraglutide on Subclinical Atherosclerosis in Patients With Type 1 Diabetes MellitusNCT05467514 · 2022-07-01
COMPLETED
Endoscopic Ultrasound Guided Gastric Botulinum Toxin Injections Versus Glucagon Like Peptide 1 Receptor Agonist in Weight LossNCT05268627 · 2022-01-27
UNKNOWN
Liraglutide (Saxenda(R)) in Adolescents With Obesity After Sleeve GastrectomyNCT04883346 · 2021-06-21
COMPLETED
SCALE KIDS: Research Study to Look at How Well a New Medicine is at Lowering Weight in Children With ObesityNCT04775082 · 2021-03-04
ACTIVE_NOT_RECRUITING
Liraglutide and Peripheral Artery DiseaseNCT04881110 · 2021-02-01
COMPLETED
Liraglutide Improve Cognitive Function in Patients With Type 2 Diabetes MellitusNCT05360147 · 2021-01-20
COMPLETED
Efficacy and Tolerance of Liraglutide for Weight Loss in Obese Type 2 Diabetic Hemodialysis PatientsNCT04529278 · 2021-01-18
UNKNOWN
Targeting Beta-cell Failure in Lean Patients With Type 2 DiabetesNCT04657939 · 2020-12-01
COMPLETED
Antigen-Lipid-Driven Monoclonal Gammopathies Targeting Epicardial FatNCT02920190 · 2020-09-01
WITHDRAWN
A Study of Tirzepatide in Overweight and Very Overweight ParticipantsNCT04311411 · 2020-08-24
COMPLETED
The Efficacy and Safety of Liraglutide on Body Weight Loss in Obese and Overweight PatientsNCT04605861 · 2020-08-18
COMPLETED
Gut Microbiome Changes Following Liraglutide Treatment in Obese Subjects or Overweight Subjects With Co-morbiditiesNCT04525300 · 2020-05-24
UNKNOWN
Harmonizing RCT-Duplicate Emulations In A Real World Replication Program (HARRP)NCT06099067 · 2020-05-15
COMPLETED
Efficacy and Safety of Liraglutide on Body Weight in Obese Subjects or Overweight Subjects With Co-morbiditiesNCT04487743 · 2020-05-09
UNKNOWN
Dulaglutide Versus Liraglutide in Obese Type 2 Diabetic Adolescents Using MetforminNCT04829903 · 2020-01-02
COMPLETED
Liraglutide Actions on the Liver: Effects on Glucose PhosphorylationNCT02198209 · 2019-12-01
WITHDRAWN
Effects of Benaglutide on Weight and Gut Microbiota in Obese PatientsNCT03986008 · 2019-12-01
UNKNOWN
Research Study to Investigate How Well Semaglutide Works Compared to Liraglutide in People Living With Overweight or ObesityNCT04074161 · 2019-09-11
COMPLETED
Replication of the LEAD-2 Diabetes Trial in Healthcare Claims DataNCT05162183 · 2019-09-01
COMPLETED
Liraglutide in Acute Minor Ischemic Stroke or High-risk Transient Ischemic Attack Patients With Type 2 Diabetes MellitusNCT03948347 · 2019-06-25
UNKNOWN
A Research Study Looking at How Victoza® Works in People With Type 2 Diabetes in Iran, Followed in Local Clinical RoutineNCT03888157 · 2019-03-10
COMPLETED
Multiple Ascending Dose Study of AMG 598 in Adults With ObesityNCT03757130 · 2018-11-26
COMPLETED
A Study Using Medical Records of Danish People With Type 2 Diabetes Comparing Empagliflozin and Glucagon-Like Peptide-1 Receptor Agonists (GLP1-RA) in the Occurrence of Serious Cardiovascular OutcomesNCT03993132 · 2018-10-01
COMPLETED
Effects of Liraglutide on the Cognitive Function in Patients With Type 2 Diabetes MellitusNCT03707171 · 2018-10-01
COMPLETED
Effects of GLP-1 RAs on Weight and Metabolic Indicators in Obese PatientsNCT03671733 · 2018-09-01
UNKNOWN
Targeting Beta Cell Dysfunction With Liraglutide or Golimumab in Longstanding T1DNCT03632759 · 2018-08-15
COMPLETED
A Regulatory Post-marketing Surveillance (rPMS) Study to Evaluate the Safety and Effectiveness of Saxenda®(Liraglutide 3.0 mg) in Obese Patients and Overweight Patients With Obesity-related Comorbidities in Routine Clinical Practice in Korea.NCT03560336 · 2018-07-05
COMPLETED
Effect of Liraglutide on Neural Responses to High Fructose Corn Syrup in Individuals With Obesity.NCT03500484 · 2018-06-06
TERMINATED
A Study to Investigate the Effect of MEDI0382 on Hepatic Glycogen Metabolism in Overweight and Obese Subjects With Type 2 Diabetes Mellitus.NCT03555994 · 2018-05-31
COMPLETED
In Market Utilisation of Liraglutide Used for Weight Management in the UK: a Study in the CPRD Primary Care DatabaseNCT03479762 · 2018-04-20
COMPLETED
A Study to Evaluate the Safety and Efficacy of JNJ-64565111 in Non-diabetic Severely Obese ParticipantsNCT03486392 · 2018-03-26
COMPLETED
Effects of Liraglutide in Chronic Obstructive Pulmonary DiseaseNCT03466021 · 2018-01-01
COMPLETED
Individualized Obesity PharmacotherapyNCT03374956 · 2017-12-11
COMPLETED
The Effect and the Pharmacogenomics Study of Liraglutide in Obese PatientsNCT04839237 · 2017-12-01
WITHDRAWN
Pilot Study of the Effect of Liraglutide 3.0 mg on Weight Loss and Gastric Functions in ObesityNCT03523273 · 2017-11-29
COMPLETED
Effect of Liraglutide on Vascular Inflammation in Type-2 DiabetesNCT03449654 · 2017-10-26
COMPLETED
Replication of the LEADER Diabetes Trial in Healthcare ClaimsNCT03936049 · 2017-09-22
COMPLETED
Stem Cell Mobilization (Plerixafor) and Immunologic Reset in Type 1 Diabetes (T1DM)NCT03182426 · 2017-08-15
COMPLETED
A Study to Evaluate the Efficacy and Safety of MEDI0382 in the Treatment of Overweight and Obese Subjects With Type 2 DiabetesNCT03235050 · 2017-08-02
COMPLETED
Research Study Comparing a New Medicine Semaglutide to Liraglutide in People With Type 2 DiabetesNCT03191396 · 2017-06-27
COMPLETED
A Study of LY3325656 in Healthy Participants and Participants With Type 2 DiabetesNCT03115099 · 2017-05-31
COMPLETED
A Trial Comparing Insulin Degludec/Liraglutide, Insulin Degludec, and Liraglutide in Chinese Subjects With Type 2 Diabetes Inadequately Controlled on Oral Antidiabetic Drugs (OADs)NCT03172494 · 2017-05-26
COMPLETED
Title: Therapeutic Targets in African-American Youth With Type 2 DiabetesNCT02960659 · 2017-05-09
COMPLETED
Cardiovascular Effects of GLP-1 Receptor ActivationNCT03101930 · 2017-05-01
COMPLETED
Safety and Efficacy of Liraglutide in Parkinson's DiseaseNCT02953665 · 2017-04-03
COMPLETED
Methodology Study To Examine 6-Week Food Intake With Liraglutide In Obese SubjectsNCT03041792 · 2017-02-20
COMPLETED
Dose-response, Safety and Efficacy of Oral Semaglutide Versus Placebo and Versus Liraglutide, All as Monotherapy in Japanese Subjects With Type 2 DiabetesNCT03018028 · 2017-01-10
COMPLETED

Trial status mix

COMPLETED107
UNKNOWN23
TERMINATED10
WITHDRAWN6
RECRUITING5
ACTIVE_NOT_RECRUITING3

Phase mix

PHASE456
PHASE335
PHASE233
NA13
PHASE112
EARLY_PHASE12

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.